Company / Current Liabilities
Arrowhead Pharmaceuticals Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$195.5M
FY2025
5-year range
$103.2M / $195.5M
FY2021-FY2025
Trend
+89.5%
vs FY2024
Sector context
#61 of 213
Health Care
What the data says
At $195M, Arrowhead Pharmaceuticals's current liabilities ranks #153 of 213 in the Health Care sector. Current Liabilities returned to growth in FY2025 after 3 years of decline, reaching $195M.
Based on SEC 10-K filings.
$195M in FY2025 with a 5-year CAGR of +36.9%.
Increased from $105M to $195M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +12.1%
- 5-Year CAGR
- +36.9%
- 10-Year CAGR
- -
Sector benchmark
#153 of 213 in Health CareTop 71% of 213This company $195.5M Sector average $1.6B
▼
-87.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +36.9%, indicating consistent growth.
- In FY2025, current liabilities increased 89.5% year-over-year.
- Ranks #61 out of 213 companies in the Health Care sector.
- Lowest current liabilities in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $195.5M | +89.5% |
| FY2024 | $103.2M | -2.2% |
| FY2023 | $105.5M | -24.1% |
| FY2022 | $138.8M | -5.2% |
| FY2021 | $146.5M | +260.2% |
| FY2020 | $40.7M | -58.1% |
| FY2019 | $97.1M | +685.0% |
| FY2018 | $12.4M | -33.9% |
| FY2017 | $18.7M | -27.1% |
| FY2016 | $25.6M | +61.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026